What is Nutex Health Inc.'s earnings per share (EPS)?

Nutex Health Inc. (NUTX) reported diluted earnings per share of $10.48 for fiscal year 2025. This represents a 8.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nutex Health Inc. (NUTX) Financials

NUTX

Trailing 12 months to June 30, 2026

Revenue $846.7M +6.9% YoY

Net Income $179.9M +218.8% YoY

EPS (Diluted) $25.27 +158.4% YoY

Free Cash Flow $274.2M +229.4% YoY

Market Cap $1.4B as of Oct 10, 2026

Price / Sales 1.7x on $846.7M revenue, trailing 12 months to June 30, 2026

Price / Earnings 7.9x on $179.9M net income, trailing 12 months to June 30, 2026

Price / Book 3.6x on $394.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NUTX SEC filings page.

Nutex Health Inc. (NUTX) reported $846.7M in revenue over the twelve months to Jun 30, 2026, up 6.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NUTX FY2025 2026-10-03

The business is scaling quickly, converting 2025 operations into cash unusually well while taxes dilute the benefit at the bottom line.

Cash conversion was much stronger than reported earnings in FY2025: operating cash flow reached $248M against net income of $70.8M. Free cash flow of $245.6M nearly matched operating cash flow, indicating that reported cash generation was not being absorbed by reinvestment.

Revenue expanded 82.4% from FY2024 to FY2025, and the operating margin widened from 27.2% to 31.5%. Costs therefore grew more slowly than sales, consistent with fixed-cost absorption rather than growth alone.

Net margin fell from 10.9% to 8.1% even as operating efficiency improved. Income-tax expense rose from $15.0M to $64.4M, while low leverage and a 3.4x current ratio indicate that the weaker bottom-line conversion was not driven by heavy debt or near-term balance-sheet pressure.

Financial Health Signals

Financial Health Score 80/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Nutex Health Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Nutex Health Inc. has an operating margin of 31.5%, meaning the company retains $31 of operating profit per $100 of revenue. This results in a moderate score of 64/100, indicating healthy but not exceptional operating efficiency. This is up from 27.2% the prior year.

Growth

Nutex Health Inc.'s revenue surged 82.4% year-over-year to $875.3M, reflecting rapid business expansion. This strong growth earns a score of 98/100.

Leverage

Nutex Health Inc. carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.41, Nutex Health Inc. holds $3.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.

Cash Flow

Nutex Health Inc. converts 28.1% of revenue into free cash flow ($245.6M). This strong cash generation earns a score of 77/100.

Returns

Nutex Health Inc. earns a strong 21.5% return on equity (ROE), meaning it generates $21 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 65/100. This is down from 39.3% the prior year.

Altman Z-Score Safe

3.72

Nutex Health Inc. scores 3.72, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Nutex Health Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

3.51x

For every $1 of reported earnings, Nutex Health Inc. generates $3.51 in operating cash flow ($248.1M OCF vs $70.8M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

12.40x

Nutex Health Inc. earns $12.40 in operating income for every $1 of interest expense ($275.6M vs $22.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$210.8M

YoY-13.6%

QoQ-2.6%

5Y CAGR+27.4%

Nutex Health Inc. generated $210.8M in revenue in Q2 2026. This represents a decrease of 13.6% from the same quarter a year earlier. Against the prior quarter it is down 2.6%.

EBITDA

$127.0M

YoY+226.3%

QoQ+46.4%

5Y CAGR+33.6%

Nutex Health Inc.'s EBITDA was $127.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 226.3% from the same quarter a year earlier. Against the prior quarter it is up 46.4%.

Net Income

$65.8M

YoY+472.1%

QoQ+40.7%

5Y CAGR+17.3%

Nutex Health Inc. reported $65.8M in net income in Q2 2026. This represents an increase of 472.1% from the same quarter a year earlier. Against the prior quarter it is up 40.7%.

EPS (Diluted)

$9.38

YoY+418.0%

QoQ+43.9%

5Y CAGR+184.9%

Nutex Health Inc. earned $9.38 per diluted share (EPS) in Q2 2026. This represents an increase of 418.0% from the same quarter a year earlier. Against the prior quarter it is up 43.9%.

Cash & Balance Sheet

Free Cash Flow

$31.7M

YoY+19.4%

QoQ-57.4%

Nutex Health Inc. generated $31.7M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 19.4% from the same quarter a year earlier. Against the prior quarter it is down 57.4%.

Cash & Debt

$205.2M

YoY+112.1%

QoQ-1.0%

5Y CAGR+112.0%

10Y CAGR+139.3%

Nutex Health Inc. held $205.2M in cash against $31.1M in long-term debt as of Q2 2026.

Shares Outstanding

YoY+3.8%

QoQ-0.5%

5Y CAGR-30.4%

Nutex Health Inc. had 7M shares outstanding in Q2 2026. This represents an increase of 3.8% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

67.0%

YoY+15.8pp

QoQ+24.7pp

5Y change+20.7pp

Nutex Health Inc.'s gross margin was 67.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 15.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 24.7 percentage points.

Operating Margin

57.8%

YoY+44.0pp

QoQ+20.2pp

5Y change+13.8pp

Nutex Health Inc.'s operating margin was 57.8% in Q2 2026, reflecting core business profitability. This is up 44.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 20.2 percentage points.

Net Margin

31.2%

YoY+38.5pp

QoQ+9.6pp

5Y change-16.0pp

Nutex Health Inc.'s net profit margin was 31.2% in Q2 2026, showing the share of revenue converted to profit. This is up 38.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.6 percentage points.

Return on Equity

16.7%

YoY+24.2pp

QoQ+3.2pp

5Y change-1.8pp

Nutex Health Inc.'s ROE was 16.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 24.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.2 percentage points.

Capital Allocation

Share Buybacks

$19.0M

QoQ-40.3%

Nutex Health Inc. spent $19.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 40.3%.

Capital Expenditures

$2.5M

YoY+238.2%

QoQ+111.5%

Nutex Health Inc. invested $2.5M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 238.2% from the same quarter a year earlier. Against the prior quarter it is up 111.5%.

R&D Spending

Not reported for Q2 2026.

NUTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NUTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K/A	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$846.7M	$875.3M+82.4%	$479.9M+93.8%	$247.6M+12.9%	$219.3M-33.9%	$331.5M	N/A	$1.4M0.0%	$1.4M+5800.9%	$23K	$0-100.0%	$475K-55.6%	$1.1M-26.9%	$1.5M-8.3%	$1.6M-10.7%	$1.8M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$14.6M	N/A	$830K+63.6%	$508K+1565.4%	$30K	$0-100.0%	$8K-98.3%	$465K-6.2%	$496K-36.7%	$784K+2.5%	$765K
Gross Profit	$434.0M	$444.3M+126.4%	$196.3M+464.4%	$34.8M+125.5%	$15.4M-91.4%	$179.3M	N/A	$536K-37.6%	$859K+11847.9%	-$7K	$0-100.0%	$467K-22.7%	$603K-37.5%	$965K+19.1%	$810K-20.5%	$1.0M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$286K-48.7%	$557K-27.5%	$768K+40.9%	$545K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$60.2M	$51.7M+23.2%	$41.9M+26.2%	$33.2M+67.7%	$19.8M+262.7%	$5.5M	N/A	$3.7M+287.8%	$946K-47.9%	$1.8M+304.3%	$449K-15.8%	$533K-26.3%	$723K-57.3%	$1.7M-29.0%	$2.4M+27.9%	$1.9M
Operating Income	$364.3M	$275.6M+110.9%	$130.7M+511.3%	-$31.8M+92.2%	-$406.6M-338.8%	$170.3M	N/A	-$6.9M-720.8%	-$840K+85.2%	-$5.7M-1169.1%	-$449K+15.8%	-$533K+26.3%	-$723K+0.5%	-$727K+53.8%	-$1.6M-86.3%	-$845K
EBITDA	N/A	$296.2M+97.9%	$149.7M+1155.4%	-$14.2M+96.4%	-$393.5M-321.1%	$177.9M	N/A	-$6.7M-704.8%	-$838K+85.3%	-$5.7M-1170.1%	-$448K+15.8%	-$532K+19.4%	-$660K+3.9%	-$687K+56.1%	-$1.6M-86.5%	-$839K
Interest Expense	$19.8M	$22.2M+11.5%	$19.9M+22.1%	$16.3M+30.6%	$12.5M+101.6%	$6.2M	N/A	$92K-16.1%	$110K-70.1%	$367K+14144.0%	$3K+182.0%	-$3K+33.3%	-$5K+91.3%	-$55K	N/A	N/A
Income Tax	$71.0M	$64.4M+328.9%	$15.0M+396.4%	-$5.1M-138.7%	$13.1M+1255.5%	$966K+432.5%	$181K	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$179.9M	$70.8M+35.9%	$52.1M+213.8%	-$45.8M+89.2%	-$424.8M-420.4%	$132.6M	N/A	-$7.1M-649.0%	-$950K-263.2%	$582K	N/A	$84K+112.2%	-$684K-373.2%	$250K+115.4%	-$1.6M-323.6%	-$383K
EPS (Basic)	N/A	$11.13+8.8%	$10.23+198.5%	-$10.39+89.6%	-$100.36-45718.2%	$0.22+22.2%	$0.18	N/A	-$0.02+71.4%	-$0.07-600.0%	-$0.01+50.0%	-$0.02+33.3%	-$0.03	$0.00+100.0%	-$0.07-250.0%	-$0.02
EPS (Diluted)	$25.27	$10.48+8.2%	$9.69	-$10.39+89.6%	-$100.36	$0.22+22.2%	$0.18	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	7M+23.0%	5M	4M+4.2%	4M	N/A	N/A	N/A	N/A	N/A	40M	29M+12.4%	26M-0.2%	26M+8.5%	24M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$210.8M-13.6%	$216.5M+2.2%	$151.7M-41.1%	$267.8M+239.9%	$244.0M+220.7%	$211.8M+214.0%	$257.6M+269.8%	$78.8M+25.6%
Gross Profit	$141.3M+13.1%	$91.7M-22.5%	$46.1M-67.4%	$154.9M+606.7%	$124.9M+453.7%	$118.3M+1065.1%	$141.6M+971.8%	$21.9M+210.2%
SG&A Expenses	$16.7M+33.4%	$14.4M+43.3%	$17.8M+39.8%	$11.3M+14.5%	$12.5M+17.3%	$10.0M+15.9%	$12.7M+50.0%	$9.9M+26.6%
Operating Income	$121.7M+261.4%	$81.3M+0.7%	$30.9M-72.9%	$130.4M+1249.1%	$33.7M+535.6%	$80.7M+5462.8%	$114.2M+536.8%	$9.7M+1276.7%
EBITDA	$127.0M+226.3%	$86.8M+1.2%	$36.1M-69.8%	$135.4M+825.0%	$38.9M+295.9%	$85.8M+1421.5%	$119.5M+656.8%	$14.6M+272.9%
Interest Expense	$4.7M-17.7%	$4.7M-23.5%	$5.0M-1.5%	$5.5M+1.3%	$5.7M+12.3%	$6.1M+37.7%	$5.1M+19.2%	$5.4M+31.3%
Income Tax	$20.8M+173.7%	$13.8M-32.4%	$9.3M+7.9%	$27.1M+491.9%	$7.6M+748.8%	$20.4M+5133.3%	$8.6M+387.1%	$4.6M+1439.6%
Net Income	$65.8M+472.1%	$46.8M+120.6%	$11.8M-80.8%	$55.4M+730.8%	-$17.7M-4761.8%	$21.2M+5928.8%	$61.7M+295.1%	-$8.8M-58.6%
EPS (Basic)	$9.58+424.7%	$6.70+79.1%	$1.50-87.3%	$8.27+580.8%	-$2.95-4114.3%	$3.74+4775.0%	$11.83+258.4%	-$1.72-37.6%
EPS (Diluted)	$9.38+418.0%	$6.52+95.8%	$1.61-85.5%	$7.76+551.2%	-$2.95-4114.3%	$3.33+4262.5%	$11.12+248.9%	-$1.72
Diluted Shares (Avg)	7M+17.1%	7M+11.3%	N/A	7M+40.7%	6M+20.6%	6M+33.0%	N/A	5M

Not reported in any period shown, so not listed: Cost of Revenue, R&D Expenses.

NUTX Balance Sheet

NUTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K/A	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$918.5M+40.2%	$655.3M+64.6%	$398.2M-7.8%	$431.8M+9.4%	$394.7M+232242.5%	$170K-97.5%	$6.7M+1389.1%	$449K-86.5%	$3.3M+551.6%	$511K-93.3%	$7.6M+2620.2%	$281K-73.8%	$1.1M+43.6%	$746K-60.6%	$1.9M
Current Assets	$538.8M+84.2%	$292.5M+221.9%	$90.8M-7.3%	$98.0M-36.4%	$154.0M+97963.9%	$157K-87.4%	$1.2M+307.1%	$305K+454.5%	$55K-89.2%	$508K-93.3%	$7.6M+2662.2%	$276K-73.7%	$1.1M+46.6%	$717K-59.2%	$1.8M
Cash & Equivalents	$185.6M+356.6%	$40.6M+84.7%	$22.0M-35.8%	$34.3M-5.2%	$36.1M+134014.2%	$27K-97.5%	$1.1M+793.3%	$119K+1162.2%	$9K-10.2%	$11K-91.4%	$122K-3.6%	$127K+372.0%	$27K-74.3%	$105K-53.4%	$225K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$2.9M+0.6%	$2.9M-15.9%	$3.4M-4.0%	$3.5M+25.6%	$2.8M	$0-100.0%	$27K	$0	$0	N/A	$21K	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$232.4M+296.7%	$58.6M+1.4%	$57.8M-48.7%	$112.8M+616682.3%	$18K-81.8%	$100K-46.2%	$186K+2876.5%	$6K	$0-100.0%	$230K+181.8%	$82K-39.6%	$135K-14.6%	$158K-41.2%	$269K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$13.9M0.0%	$13.9M-18.4%	$17.1M+0.3%	$17.0M+1393.1%	$1.1M	$0-100.0%	$3.5M	$0	N/A	$0-100.0%	$6.7M	N/A	N/A	N/A	$111K
Total Liabilities	$495.1M+6.1%	$466.8M+46.3%	$319.1M+2.5%	$311.4M+53.4%	$203.1M+15476.9%	$1.3M-73.0%	$4.8M+148.3%	$1.9M-55.0%	$4.3M-32.2%	$6.4M+5.0%	$6.1M+2030.1%	$285K-44.6%	$515K+17.0%	$440K+52.5%	$289K
Current Liabilities	$157.9M+2.4%	$154.2M+164.5%	$58.3M+6.3%	$54.9M+45.6%	$37.7M+3167.1%	$1.2M-75.0%	$4.6M+341.6%	$1.0M+8.8%	$960K-85.0%	$6.4M+5.0%	$6.1M+2030.1%	$285K-44.6%	$515K+17.0%	$440K+52.5%	$289K
Non-Current Liabilities	$337.2M+7.9%	$312.6M+19.8%	$260.8M+1.7%	$256.6M+55.1%	$165.4M+110152.0%	$150K-32.9%	$224K-75.2%	$903K-73.2%	$3.4M	$0-100.0%	$3.2M	$0	$0	$0	$0
Long-Term Debt	$29.2M+29.9%	$22.5M-14.6%	$26.3M+14.2%	$23.1M-70.8%	$78.8M	$0	$0-100.0%	$300K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$329.4M+148.8%	$132.4M+115.5%	$61.5M-35.9%	$95.9M-16.4%	$114.7M+10212.2%	-$1.1M-161.0%	$1.9M+224.1%	-$1.5M-50.2%	-$997K+83.0%	-$5.9M-475.9%	$1.6M+34865.4%	-$4K-100.8%	$556K+81.9%	$306K-80.9%	$1.6M
Retained Earnings	-$286.2M+19.8%	-$357.0M+12.7%	-$409.1M-12.6%	-$363.3M-455.1%	$102.3M+661.6%	-$18.2M-45.0%	-$12.6M-130.5%	-$5.5M+43.5%	-$9.6M+5.7%	-$10.2M-265.6%	-$2.8M-198.2%	$2.9M+229.7%	-$2.2M+10.2%	-$2.4M-197.0%	-$824K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$964.6M+14.7%	$957.3M+25.6%	$918.5M+40.2%	$964.5M+120.0%	$841.0M+99.1%	$761.9M+88.5%	$655.3M+64.6%	$438.5M-8.6%
Current Assets	$585.6M+23.8%	$579.6M+44.4%	$538.8M+84.2%	$592.7M+394.7%	$473.0M+315.4%	$401.5M+300.1%	$292.5M+221.9%	$119.8M+33.3%
Cash & Equivalents	$205.2M+112.1%	$207.3M+144.7%	$185.6M+356.6%	$166.0M+254.0%	$96.7M+137.0%	$84.7M+182.4%	$40.6M+84.7%	$46.9M+74.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$4.2M+84.9%	$4.7M+50.1%	$2.9M+0.6%	$3.2M+39.8%	$2.3M-17.6%	$3.1M+4.8%	$2.9M-15.9%	$2.3M-15.8%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$295.1M+379.5%	$232.4M+296.7%	$62.7M+17.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M-18.4%	$13.9M-18.4%	$13.9M-22.4%
Total Liabilities	$457.3M-9.3%	$515.3M+1.7%	$495.1M+6.1%	$526.5M+46.8%	$504.2M+48.1%	$506.6M+56.2%	$466.8M+46.3%	$358.7M-4.3%
Current Liabilities	$117.2M-39.8%	$184.4M-6.0%	$157.9M+2.4%	$185.5M+174.5%	$194.9M+171.9%	$196.2M+227.6%	$154.2M+164.5%	$67.6M+0.4%
Non-Current Liabilities	$340.1M+10.0%	$330.8M+6.6%	$337.2M+7.9%	$341.0M+17.1%	$309.3M+15.1%	$310.5M+17.4%	$312.6M+19.8%	$291.2M-5.3%
Long-Term Debt	$31.1M+52.0%	$24.3M+11.6%	$29.2M+29.9%	$25.6M-4.6%	$20.5M-8.7%	$21.7M-17.4%	$22.5M-14.6%	$26.8M+38.8%
Total Equity	$394.3M+67.6%	$346.3M+95.7%	$329.4M+148.8%	$317.2M+424.8%	$235.3M+275.0%	$176.9M+180.8%	$132.4M+115.5%	$60.4M-32.8%
Retained Earnings	-$173.5M+50.9%	-$239.4M+28.7%	-$286.2M+19.8%	-$298.0M+28.8%	-$353.5M+13.7%	-$335.8M+18.0%	-$357.0M+12.7%	-$418.6M-10.9%

NUTX Cash Flow Statement

NUTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K/A	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$279.6M	$248.1M+971.7%	$23.2M+1741.9%	$1.3M-97.5%	$50.6M-70.8%	$173.4M	N/A	-$4.0M-741.7%	-$480K+32.8%	-$715K-160.6%	-$274K-710.6%	$45K-71.8%	$159K+186.9%	-$183K+64.7%	-$519K+21.3%	-$659K
Depreciation & Amortization	N/A	$20.5M+8.2%	$19.0M+7.8%	$17.6M+34.0%	$13.1M+71.4%	$7.7M	N/A	$156K+5713.5%	$3K+135.9%	$1K+140.6%	$473-28.5%	$662-99.0%	$63K+57.1%	$40K+360.0%	$9K+47.9%	$6K
Stock-Based Compensation	N/A	$107.8M+83175.8%	-$130K	N/A	$190K-95.3%	$4.0M+56.6%	$2.6M+471.4%	$450K+188.7%	$156K-83.1%	$924K+61521.7%	$2K	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	$5.5M	$2.5M+9.6%	$2.3M-75.7%	$9.5M-35.1%	$14.6M-60.4%	$36.9M	N/A	$84K	$0	N/A	N/A	-$2K-11.3%	-$2K	N/A	-$8K-58.4%	-$19K
Free Cash Flow	$274.2M	$245.6M+1078.0%	$20.8M+353.0%	-$8.2M-122.9%	$36.0M-73.6%	$136.5M	N/A	-$4.1M-759.2%	-$480K	N/A	N/A	$43K-72.6%	$157K	N/A	-$527K+22.4%	-$679K
Investing Cash Flow	-$9.1M	-$5.2M+6.5%	-$5.6M+50.1%	-$11.2M-159.1%	-$4.3M+88.3%	-$37.0M	N/A	-$748K-539.7%	-$117K-5805.6%	$2K+120.5%	-$10K-646.5%	$2K+138.6%	-$5K-363.3%	$2K-99.6%	$418K+1.1%	$413K
Financing Cash Flow	-$160.4M	-$97.9M-9077.9%	$1.1M+148.1%	-$2.3M+95.3%	-$48.1M+61.8%	-$125.9M	N/A	$5.7M+714.0%	$705K-1.0%	$712K+312.6%	$172K+436.3%	-$51K+5.9%	-$55K-152.7%	$104K+641.1%	-$19K	N/A
Share Buybacks	N/A	$5.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$34.2M+25.5%	$75.5M+48.2%	$70.4M+130250.0%	$99.5M+1366.0%	$27.3M+105.6%	$51.0M+1570.4%	$54K+103.0%	$6.8M+244.9%
Depreciation & Amortization	$5.3M+1.3%	$5.5M+7.9%	$5.2M-1.8%	$5.0M+0.6%	$5.2M+15.8%	$5.1M+21.6%	$5.3M+12.8%	$5.0M+4.8%
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	$15.9M	N/A	N/A
Capital Expenditures	$2.5M+238.2%	$1.2M+1776.6%	$1.4M+256.7%	$302K-51.1%	$751K+34.3%	$64K-91.3%	$395K	$617K
Free Cash Flow	$31.7M+19.4%	$74.3M+46.0%	$69.0M+20328.7%	$99.2M+1507.7%	$26.5M+108.7%	$50.9M+2095.9%	-$341K	$6.2M
Investing Cash Flow	-$2.5M-1395.9%	-$1.2M-1776.6%	-$5.1M-52.0%	-$302K-13.1%	$196K+115.4%	-$64K+91.3%	-$3.3M-485.5%	-$267K+92.6%
Financing Cash Flow	-$35.2M-127.8%	-$49.5M-627.4%	-$45.8M-1433.5%	-$29.9M-7001.4%	-$15.4M-1200.4%	-$6.8M-219.8%	-$3.0M+23.7%	-$421K+90.2%
Share Buybacks	$19.0M	$31.7M	N/A	N/A	$0	$0	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid.

NUTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NUTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K/A	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	50.8%+9.9pp	40.9%+26.8pp	14.0%+7.0pp	7.0%-47.0pp	54.1%	N/A	39.2%-23.6pp	62.9%+94.4pp	-31.6%	N/A	98.3%+41.9pp	56.5%-9.6pp	66.0%+15.2pp	50.8%-6.3pp	57.1%
Operating Margin	31.5%+4.3pp	27.2%+40.1pp	-12.8%	-185.4%	51.4%	N/A	-504.8%	-61.5%	-24574.5%	N/A	-112.3%	-67.7%-17.9pp	-49.8%+48.9pp	-98.7%-51.4pp	-47.3%
Net Margin	8.1%-2.8pp	10.8%+29.3pp	-18.5%	-193.7%	40.0%	N/A	-520.8%	-69.5%	2512.6%	N/A	17.7%+81.7pp	-64.0%-81.2pp	17.1%	-101.9%	-21.5%
Return on Equity	21.5%-17.9pp	39.3%+113.9pp	-74.5%+368.6pp	-443.1%-558.8pp	115.7%	N/A	-382.9%	N/A	N/A	N/A	5.4%	N/A	45.0%+576.3pp	-531.2%-507.3pp	-23.9%
Return on Assets	7.7%-0.2pp	8.0%+19.4pp	-11.5%+86.9pp	-98.4%-132.0pp	33.6%	N/A	-106.3%+105.1pp	-211.4%-228.9pp	17.5%	N/A	1.1%+244.8pp	-243.7%-267.1pp	23.4%+241.1pp	-217.7%-197.4pp	-20.3%
Current Ratio	3.41+1.5x	1.90+0.3x	1.56-0.2x	1.79-2.3x	4.09+4.0x	0.14-0.1x	0.270.0x	0.29+0.2x	0.060.0x	0.08-1.2x	1.26+0.3x	0.97-1.1x	2.04+0.4x	1.63-4.5x	6.10
Debt-to-Equity	0.09-0.1x	0.17-0.3x	0.43+0.2x	0.24-0.4x	0.69	N/A	0.00	N/A	N/A	N/A	3.89	N/A	0.93-0.5x	1.44+1.3x	0.18
Asset Turnover	0.95+0.2x	0.73+0.1x	0.62+0.1x	0.51-0.3x	0.84	N/A	0.20-2.8x	3.04+3.0x	0.010.0x	0.00-0.1x	0.06-3.7x	3.81+2.4x	1.36-0.8x	2.14+1.2x	0.94
FCF Margin	28.1%+23.7pp	4.3%+7.7pp	-3.3%-19.7pp	16.4%-24.8pp	41.2%	N/A	-301.9%	-35.1%	N/A	N/A	9.1%-5.6pp	14.7%	N/A	-33.1%+5.0pp	-38.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	67.0%+15.8pp	42.4%-13.5pp	30.4%-24.6pp	57.8%+30.0pp	51.2%+21.6pp	55.9%+40.8pp	55.0%+36.0pp	27.8%+16.6pp
Operating Margin	57.8%+44.0pp	37.5%-0.6pp	20.4%-24.0pp	48.7%+36.4pp	13.8%+6.8pp	38.1%+35.9pp	44.3%+81.9pp	12.3%+13.6pp
Net Margin	31.2%+38.5pp	21.6%+11.6pp	7.8%-16.1pp	20.7%+31.9pp	-7.2%-6.8pp	10.0%+10.6pp	23.9%+69.3pp	-11.2%-2.3pp
Return on Equity	16.7%+24.2pp	13.5%+1.5pp	3.6%-43.0pp	17.5%+32.0pp	-7.5%-6.9pp	12.0%+12.6pp	46.6%+98.0pp	-14.5%-8.4pp
Return on Assets	6.8%+8.9pp	4.9%+2.1pp	1.3%-8.1pp	5.8%+7.8pp	-2.1%-2.0pp	2.8%+2.9pp	9.4%+17.3pp	-2.0%-0.8pp
Current Ratio	5.00+2.6x	3.14+1.1x	3.41+1.5x	3.20+1.4x	2.43+0.8x	2.05+0.4x	1.90+0.3x	1.77+0.4x
Debt-to-Equity	0.080.0x	0.07-0.1x	0.09-0.1x	0.08-0.4x	0.09-0.3x	0.12-0.3x	0.17-0.3x	0.44+0.2x
Asset Turnover	0.22-0.1x	0.23-0.1x	0.17-0.2x	0.28+0.1x	0.29+0.1x	0.28+0.1x	0.39+0.2x	0.180.0x
FCF Margin	15.0%+4.2pp	34.3%+10.3pp	45.5%+45.6pp	37.0%+29.2pp	10.9%-5.8pp	24.0%+20.6pp	-0.1%	7.8%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Nutex Health Inc. NUTX	FY2025	$875.3M	$70.8M	8.1%	$1.4B	80/100
Auna S.A. AUNA	FY2025	N/A	N/A	N/A	$377.7M	—
agilon health, inc. AGL	FY2025	$5.9B	-$391.3M	-6.6%	$1.4B	39/100
InnovAge Holding Corp. INNV	FY2026	$989.7M	-$2.5M	-0.3%	$1.2B	48/100
Sonida Senior Living, Inc. SNDA	FY2025	$381.1M	-$72.5M	-19.0%	$1.7B	47/100
Enhabit, Inc. EHAB	FY2025	$1.1B	-$4.6M	-0.4%	$706.9M	28/100

Where Nutex Health Inc. Ranks

Frequently Asked Questions

What is Nutex Health Inc.'s annual revenue?

Nutex Health Inc. (NUTX) reported $875.3M in total revenue for fiscal year 2025. This represents a 82.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Nutex Health Inc.'s revenue growing?

Nutex Health Inc. (NUTX) revenue grew by 82.4% year-over-year, from $479.9M to $875.3M in fiscal year 2025.

Is Nutex Health Inc. profitable?

Yes, Nutex Health Inc. (NUTX) reported a net income of $70.8M in fiscal year 2025, with a net profit margin of 8.1%.

What is Nutex Health Inc.'s EBITDA?

Nutex Health Inc. (NUTX) had EBITDA of $296.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Nutex Health Inc. have?

As of fiscal year 2025, Nutex Health Inc. (NUTX) had $185.6M in cash and equivalents against $29.2M in long-term debt.

What is Nutex Health Inc.'s gross margin?

Nutex Health Inc. (NUTX) had a gross margin of 50.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Nutex Health Inc.'s operating margin?

Nutex Health Inc. (NUTX) had an operating margin of 31.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Nutex Health Inc.'s net profit margin?

Nutex Health Inc. (NUTX) had a net profit margin of 8.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Nutex Health Inc.'s return on equity (ROE)?

Nutex Health Inc. (NUTX) has a return on equity of 21.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Nutex Health Inc.'s free cash flow?

Nutex Health Inc. (NUTX) generated $245.6M in free cash flow during fiscal year 2025. This represents a 1078.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nutex Health Inc.'s operating cash flow?

Nutex Health Inc. (NUTX) generated $248.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Nutex Health Inc.'s total assets?

Nutex Health Inc. (NUTX) had $918.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Nutex Health Inc.'s capital expenditures?

Nutex Health Inc. (NUTX) invested $2.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Nutex Health Inc. buy back shares?

Yes, Nutex Health Inc. (NUTX) spent $5.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Nutex Health Inc. have outstanding?

Nutex Health Inc. (NUTX) had 7M shares outstanding as of fiscal year 2025.

What is Nutex Health Inc.'s current ratio?

Nutex Health Inc. (NUTX) had a current ratio of 3.41 as of fiscal year 2025, which is generally considered healthy.

What is Nutex Health Inc.'s debt-to-equity ratio?

Nutex Health Inc. (NUTX) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nutex Health Inc.'s return on assets (ROA)?

Nutex Health Inc. (NUTX) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Nutex Health Inc.'s P/E ratio?

Nutex Health Inc. (NUTX) trades at 7.9x earnings, its market capitalization divided by net income of $179.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Nutex Health Inc.'s price-to-sales ratio?

Nutex Health Inc. (NUTX) trades at 1.7x sales, its market capitalization divided by revenue of $846.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Nutex Health Inc.'s Altman Z-Score?

Nutex Health Inc. (NUTX) has an Altman Z-Score of 3.72, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Nutex Health Inc.'s Piotroski F-Score?

Nutex Health Inc. (NUTX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nutex Health Inc.'s earnings high quality?

Nutex Health Inc. (NUTX) has an earnings quality ratio of 3.51x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Nutex Health Inc. cover its interest payments?

Nutex Health Inc. (NUTX) has an interest coverage ratio of 12.40x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Nutex Health Inc.?

Nutex Health Inc. (NUTX) scores 80 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.